Randomized phase 3 study of first-line AZD3759 (zorifertinib) versus gefitinib or erlotinib in EGFR-mutant (EGFRm+) non–small-cell lung cancer (NSCLC) with …

YL Wu, Q Zhou, J Wang, Y Yu, L Xing, Y Wang… - 2023 - ascopubs.org
9001 Background: Patients (pts) with EGFR m+ NSCLC have high rates of CNS metastasis,
few treatment options, and a poor prognosis. So far there are no solid evidence from head to …
被引用次数：12 相关文章

Randomized phase 3 study of first-line AZD3759 (zorifertinib) versus gefitinib or erlotinib in EGFR-mutant (EGFRm (+)) non-small-cell lung cancer (NSCLC) with …

YL Wu, Q Zhou, J Wang, Y Yu, LG Xing… - JOURNAL OF …, 2023 - scholarworks.bwise.kr
ScholarWorks@SUNGKYUNKWAN UNIVERSITY: Randomized phase 3 study of first-line
AZD3759 (zorifertinib) versus gefitinib or erlotinib in EGFR-mutant (EGFRm(+)) non-small-cell …